• ICG001: Applied Use of a Wnt/β-Catenin Pathway Inhibitor in

  2026-05-10

  ICG001 enables precise modulation of Wnt/β-catenin signaling, powering advanced experimental workflows in EMT and fibrosis research. Explore protocol-driven insights, troubleshooting strategies, and translational use-cases for dissecting CBP/β-catenin interactions with APExBIO’s trusted reagent.

• Canagliflozin as an SGLT2 Inhibitor: Workflow Innovations in

  2026-05-09

  Canagliflozin, a potent SGLT2 inhibitor from APExBIO, empowers diabetes and renal researchers to probe beyond glucose lowering—enabling advanced mitochondrial and kidney-protective assays. This guide translates recent mechanistic discoveries into actionable protocol enhancements, troubleshooting insights, and practical parameters for metabolic disease models.

• AMD-070 Hydrochloride: Applied Workflows with CXCR4 Antagoni

  2026-05-08

  Mavorixafor hydrochloride (AMD-070 hydrochloride) enables translational researchers to precisely modulate the CXCR4 signaling axis across rare immunodeficiencies and anti-HIV models. This article breaks down protocol design, troubleshooting, and integration strategies for leveraging this potent, oral CXCR4 antagonist from APExBIO, grounded in the latest clinical and workflow evidence.

• MLN8237 (Alisertib) in Trained Immunity and Tumor Progressio

  2026-05-08

  Explore how MLN8237 (Alisertib), a selective Aurora A kinase inhibitor, uniquely modulates trained immunity and tumor biology. This article delivers a deeper scientific perspective on epigenetic and metabolic mechanisms, distinguishing itself from protocol-focused resources.

• GLP-1 (9-36) amide: Precision Antagonist for GLP-1R Research

  2026-05-07

  GLP-1 (9-36) amide is a rigorously validated peptide antagonist of the human GLP-1 receptor, supporting high-specificity investigations in metabolic regulation and type 2 diabetes research. This article details its mechanism, evidence base, and protocol integration, emphasizing its critical role in dissecting GLP-1 receptor signaling.

• Bradykinin (BA5201): Technical Guidance for Lab Researchers

  2026-05-07

  Bradykinin (SKU BA5201) is an endothelium-dependent vasodilator peptide widely used to model vascular permeability, smooth muscle contraction, and pain/inflammation pathways in controlled research settings. This product is suitable for in vitro and ex vivo assay workflows requiring reliable, rapid vasodilator responses. It should not be used for diagnostic or clinical applications.

• DCPS as an m7G Biomarker in Diabetic Foot Ulcer Healing

  2026-05-06

  This study identifies the decapping scavenger enzyme (DCPS), an m7G-related gene, as a novel biomarker and regulator of epithelial cell function in diabetic foot ulcers (DFU). Using integrated transcriptomic, functional, and cell cycle analyses, the authors demonstrate DCPS’s role in modulating cell proliferation and migration, offering new insight for wound healing research and biomarker-driven therapeutic strategies.

• Adipose-Neural Axis Drives Arrhythmias via Leptin-NPY Pathwa

  2026-05-06

  Fan et al. (2024) establish a mechanistic link between epicardial adipose tissue, sympathetic neural activation, and cardiac arrhythmias using an advanced co-culture model. Their findings highlight the leptin–NPY axis as a key driver of arrhythmogenesis and nominate molecular targets for future intervention.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Precision Tools fo

  2026-05-05

  Explore how 5-(N,N-dimethyl)-Amiloride hydrochloride enables advanced, quantitative dissection of endothelial ion transport, intracellular pH regulation, and cellular injury in sepsis models. This article offers a novel assay-design perspective, connecting practical protocol decisions to recent biomarker discoveries.

• Oxaliplatin: Optimizing Platinum-Based Chemotherapeutic Work

  2026-05-05

  Oxaliplatin’s unique DNA adduct formation underpins its potent cytotoxicity against diverse tumor models, making it indispensable for advanced cancer chemotherapy research. Discover protocol refinements, troubleshooting strategies, and actionable insights from cutting-edge genomics to maximize Oxaliplatin’s translational impact.

• Zoledronic Acid: ECM Targets and Translational Research Fron

  2026-05-04

  This thought-leadership article bridges mechanistic insights into Zoledronic Acid’s action as a nitrogen-containing bisphosphonate with strategic guidance for translational researchers. Integrating recent multiomics findings on extracellular matrix (ECM) turnover and mitochondrial metabolism in vascular pathology, the article delineates protocol best practices, contextualizes current evidence within the competitive landscape, and provides a forward-looking outlook for oncology and bone disease research. The discussion highlights how APExBIO’s Zoledronic Acid enables next-generation exploration of cell death and ECM modulation, going beyond standard product listings to inform high-impact study design.

• SAR131675 in Lymphatic Endothelial Biology: Precision, Pitfa

  2026-05-04

  Explore the pivotal role of SAR131675, a selective VEGFR-3 inhibitor, in unraveling lymphangiogenesis and tumor biology. This article uniquely examines its assay optimization, selectivity challenges, and translational lessons from metabolic liabilities.

• RSL3: Applied Workflows with a Glutathione Peroxidase 4 Inhi

  2026-05-03

  Harnessing (1S,3R)-RSL3’s precision as a glutathione peroxidase 4 inhibitor, researchers can dissect ferroptosis and redox vulnerabilities in RAS-driven cancers with unprecedented clarity. This guide delivers actionable workflows, troubleshooting insights, and protocol upgrades for optimal use of RSL3 in cancer biology and oxidative stress research.

• Sulfamonomethoxine: Applied Protocols in Veterinary and Aqua

  2026-05-02

  Sulfamonomethoxine (SMM) stands out as a broad-spectrum veterinary antibiotic with proven efficacy and unique environmental considerations. This article translates the latest experimental breakthroughs into actionable workflows, offering troubleshooting guidance and sustainability insights to maximize research and industry impact.

• JHU-083: Precision Glutaminase Antagonism for Neuro-Redox Re

  2026-05-01

  JHU-083, a potent 6-diazo-5-oxo-L-norleucine precursor, empowers advanced glutaminase pathway research across neurological and redox models. Its high solubility, selectivity, and workflow flexibility make it indispensable for dissecting glutamate excitotoxicity and experimental cerebral malaria mechanisms.

16213 records 4/1081 page Previous Next 12345 下5页 Last page